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Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. Ultrasound-based transient elastography (TE) or TE of 
the liver is a noninvasive tool for effectively evaluating liver stiffness and fibrosis. The study aimed to compare the accuracy of TE as assessed by 
Fibroscan with liver biopsy in staging fibrosis in patients with NAFLD. Consecutive NAFLD patients (N = 72) were prospectively enrolled. TE 
evaluation was performed with Fibroscan and compared with liver biopsy, which is a reference standard. Fibrosis was staged according to the 
METAVIR scoring system (Meta-analysis of Histological Data in Viral Hepatitis). TE scores and biopsy-related fibrosis stages were correlated. 
Diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) of TE was evaluated. Data were analyzed using software 
R v3.6.3. Liver biopsy showed that 36.11% of patients did not exhibit fibrosis, whereas 25, 16.67, 15.28, and 6.94% of patients had stage F1 (por-
tal/mild fibrosis), F2 (periportal/moderate fibrosis), F3 (bridging/severe fibrosis), and F4 (cirrhosis/advanced fibrosis), respectively. TE showed 
that 50% of patients had cirrhosis, whereas 20.83,15.28, and 13.86% of patients had mild, moderate, and severe fibrosis, respectively. TE had 71% 
accuracy, 89% sensitivity, and 38% specificity in diagnosing the severity of fibrosis. Hence, it can be implemented as a noninvasive alternative 
diagnostic tool for understanding the severity of fibrosis in patients with NAFLD. Moreover, it can also be used for quick early diagnosis of 
NAFLD, reliable staging of fibrosis, and understanding the need for liver transplantation in patients with NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon cause of chronic liver disease globally with an estimated 
prevalence of 20–30% (1, 2). NAFLD is characterized by 
predominant storage of lipids in hepatocytes and subsequent 
inflammatory progression, resulting in steatohepatitis, which 
is not due to alcohol consumption (3). Risk factors for 
NAFLD include obesity, dyslipidemia, type 2 diabetes mel-
litus, metabolic syndrome, hypothyroidism, and insulin resis-
tance (4). The histologic spectrum of NAFLD comprises 
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deficiency; and hemochromatosis. Moreover, patients who 
fulfilled the inclusion criteria but did not provide their con-
sent were also excluded.
Methodology
Demographic characteristics of patients were recorded. TE 
was performed on the right lobe of the liver through inter-
costal spaces using FibroScan® (12) with patients lying in 
the dorsal decubitus position and the right arm in maxi-
mum abduction. For each patient, 10 successful acquisitions 
were performed, the median value was calculated, and the 
liver stiffness was expressed in kilopascals (kPa). Comorbid 
conditions, such as diabetes mellitus, hypertension, dyslipid-
emia, and hypothyroidism, were evaluated and recorded. The 
patients were further subjected to liver biopsy, and fibrosis 
was staged from F1 to F4 according to the METAVIR scor-
ing system—a scoring system for grading and staging the 
histological lesions in NAFLD proposed by Brunt et al. and 
Pais et al. (13, 14). Subsequently, liver stiffness was correlated 
with the stages of fibrosis according to liver biopsy. All data 
were recorded in a structured patient-specific pro forma.
Statistical analysis
Data were analyzed using R software version 3.6.3 and 
Excel. Categorical and continuous variables are presented 
in the form of the frequency with percentages and mean 
(± standard deviation), respectively. Chi-square test was used 
to analyze categorical data, and Welch analysis of variance 
with suitable post hoc test was used to compare continuous 
data. P-value < 0.05 was considered statistically significant.
Results
The mean age of patients was 42.47 ± 17.86 years. Females 
comprised 63.89% of the sample size. Twenty-six (36.11%) 
patients were overweight with a body mass index (BMI) 
of 25.0–29.9 kg/m2, 18 (25%) were obese (≥30.0 kg/m2), 14 
(19.44%) were underweight (≤18.5 kg/m2), and only 14 
(19.44%) had BMI in normal range (18.5–24.9 kg/m2). On 
upper GI endoscopy, 41 (56.94%) patients exhibited no vari-
ces, whereas 20 (27.78%) and 11 (15.28%) patients exhibited 
large and small varices, respectively.
Out of 72 patients, 43 (59.6%) patients had diabetes 
mellitus, 1 (1.9%) patient had hypertension, 34 (46.2%) 
patients had dyslipidemia, and 19 (26.9%) patients had 
 hypothyroidism. Of the 43 patients with diabetes mellitus, 
11 (25.58%), 11 (25.58%), 7 (16.28%), 7 (16.28%), 4 (9.30%), 
and 3 (6.97%) were suffering from diabetes for years >10, 
5–10, 3–5, 1–2, 0, and <1, respectively.
Based on the TE scorecard, it was observed that 36 (50%) 
patients had a score of >13 (cirrhosis), whereas 15 (20.83%), 
simple steatosis, nonalcoholic steatohepatitis, fibrosis, and 
cirrhosis (5). NAFLD is the hepatic manifestation of meta-
bolic syndrome (2).
Early detection of NAFLD and staging of fibrosis are cru-
cial for identifying patients with potentially aggressive fatty 
liver disease (6). To diagnose NAFLD, patients are clinically, 
biochemically, and radiographically evaluated. Presently, 
liver biopsy is the gold standard for distinguishing simple 
steatosis from nonalcoholic steatohepatitis as well as staging 
and grading of fibrosis in patients with NAFLD (5). Liver 
biopsy assesses the prognosis of the disease in response to 
medical interventions. However, the technique is invasive and 
expensive and presents sampling errors, potential complica-
tions, and inter- and intra-observer variability. Hence, it is 
impractical for frequent evaluations on a regular basis (5).
Currently, noninvasive techniques that are highly sensitive 
and specific are being studied extensively (5). These tech-
niques comprise the biological approach using serum bio-
markers—including hyaluronic acid, collagen, serum alanine 
aminotransferase (ALT), aspartate aminotransferase (AST)/
ALT ratio, and AST/platelet ratio—as well as the physical 
approach based on imaging modalities to measure liver stiff-
ness/elasticity, including transient elastography (TE) (7).
TE using FibroScan® is a specialized ultrasound device 
that assesses liver stiffness sonographically by estimating the 
velocity of shear wave propagation, which implies that faster 
the propagation, stiffer the liver tissue (8). To evaluate fibro-
sis, TE values are further interpreted based on clinical and 
morphological data. TE is used for the evaluation of patients 
with numerous liver disorders, including NAFLD, and is pre-
ferred by clinicians due to its noninvasiveness, simplicity, and 
rapid outcomes in an outpatient setting (9).
Herein, we aimed to evaluate and compare the accuracy of 
simple noninvasive TE and conventional invasive liver biopsy 
in assessing the degrees of fibrosis in patients with NAFLD.
Materials and Methods
From January 2016 to December 2017, a prospective obser-
vational study was conducted including 72 patients with 
NAFLD attending the outpatient clinic in the Department 
of Medicine and Gastroenterology services at a tertiary care 
hospital in Bengaluru. The sample size was calculated as 
described by Jamali et al. and Charan et al. (10, 11). Written 
informed consent was obtained from all patients. Patients in 
the age group of 20–70 years who exhibited deranged liver 
enzymes and fatty liver—as diagnosed on ultrasound exam-
ination—were consecutively included in the study. Exclusion 
criteria included patients with a history of alcohol consump-
tion of >20 g/day (during the last 5 years); chronic drug 
use; the presence of hepatitis B, hepatitis C, or HIV; bili-
ary obstruction on ultrasonography; malabsorption; preg-
nancy; any cardiorespiratory comorbidities; α1-antitrypsin 
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Discussion
NAFLD is a global health crisis leading to chronic liver dis-
eases worldwide. It is more prevalent in males than females, 
and the risk of developing NAFLD increases with age (15). 
Early diagnosis of NAFLD is crucial for better prognosis 
and improved patient outcome. Liver biopsy is considered 
as the gold standard for diagnosing fibrosis in patients with 
NAFLD; however, it is invasive and not always feasible (6). 
Herein, the present study compared the accuracy of nonin-
vasive TE with that of gold standard invasive liver biopsy for 
assessing fibrosis in patients with NAFLD.
TE is a quick, noninvasive, and reproducible method. It 
does not present any discomfort or potential risks to patients. 
Although the technique has been more widely implemented 
in the diagnosis of diseases such as chronic hepatitis C, it is 
not yet fully validated in NAFLD (16).
11 (15.28%), and 10 (13.86%) patients had scores of ≤7.5 
(mild fibrosis), 7.6–9.9 (moderate fibrosis), and 10–12.9 
(severe fibrosis), respectively.
According to the findings of liver biopsy and METAVIR 
scoring system, 26 (36.11%) patients did not exhibit fibro-
sis (stage F0), whereas 18 (25%), 12 (16.67%), 11 (15.28%), 
and 5 (6.94%) were in stage F1 (portal/mild fibrosis), F2 
(periportal/ moderate fibrosis), F3 (bridging/severe fibrosis), 
and F4 (cirrhosis/advanced fibrosis), respectively.
The correlation between TE and liver biopsy findings are 
depicted in Table 1.
Using the chi-square test with simulation in the present 
study, liver biopsy and TE were found to be significantly asso-
ciated with each other (P = 0.0465). In addition, we also tried 
to see the correlation between endoscopy and TE. Here too 
there was a significant association with each other (P = 0.005).
For evaluating the correlation between liver biopsy, TE, 
and endoscopy, patients exhibiting stage F0 on liver biopsy, 
mild fibrosis on TE, and no varices on endoscopy were clas-
sified as the “no fibrosis” group. Considering this, 46 patients 
on liver biopsy, 31 patients on endoscopy, and 57 patients 
on TE were listed under “yes,” whereas 26 patients on liver 
biopsy, 41 patients on endoscopy, and 15 patients on TE 
were listed under “no” for evaluating the correlation between 
the three as shown in Table 2.
A strong correlation was obtained between TE and 
liver biopsy (P = 0.0143), and no correlation was observed 
between endoscopy and liver biopsy (P = 0.0659).
Table 3 presents the sensitivity and specificity of TE, com-
pared to liver biopsy.
Compared to liver biopsy, TE was found to have 71% 
accuracy along with 89% sensitivity and 38% specificity in 
staging fibrosis in patients with NAFLD.
Table 1: Correlation between liver biopsy, endoscopy, and Fibroscan
Fibroscan P-value
≤7.5 KPa 7.6–9.9 KPa 10–12.9 KPa ≥13 KPa
Liver biopsy F0 10 (38.46%) 5 (19.23%) 4 (15.38%) 7 (26.92%) 0.0465*
F1 0 0 1 (20%) 4 (80%)
F2 2 (18.18%) 2 (18.18%) 3 (27.27%) 4 (36.36%)
F3 3 (25%) 2 (16.67%) 1 (8.33%) 6 (50%)
F4 0 2 (11.11%) 1 (5.56%) 15 (83.33%)
Endoscopy No varices 15 (36.59%) 9 (21.95%) 5 (12.20%) 12 (29.27%) 0.005*
Small varices 0 2 (18.18%) 0 9 (81.82%)
Large varices 0 0 5 (25%) 15 (75%)
The values represent number of patients (respective percentage). *Denotes statistically significant.




Fibroscan Yes 41 16 0.0143*
No 5 10
Endoscopy Yes 23 8 0.0659
No 23 18
The values represent number of patients. *Denotes 
statistically significant.
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In the present study, the sensitivity and specificity of TE 
were 89% and 38%, respectively. Reportedly, as the stages 
of fibrosis increase, the sensitivity and specificity of the TE 
increase to better diagnose fibrosis in patients with NAFLD, 
suggesting that TE can be implemented to exclude liver cir-
rhosis (16, 17). Nevertheless, future studies are required to 
confirm this.
Liver stiffness is influenced by histological parameters, 
including chronic liver inflammation and spontaneous surge 
in liver enzymes (18). The findings of the present study and 
other published literature suggest that the reliability and 
accuracy of TE are altered due to factors such as chronic 
inflammatory activity, resulting in an overestimation of fibro-
sis (18). In the present study, TE was more accurate in diag-
nosing F4 fibrosis, and it overestimated the early stages of 
fibrosis. This may be attributable to the fact that TE is more 
strongly related to the degree of fibrosis as compared to the 
METAVIR scoring system used in liver biopsy findings (19). 
Compliant with the literature, the present study suggests that 
TE is as accurate as liver biopsy in staging fibrosis, mainly F4 
fibrosis (20).
In patients with NAFLD, higher BMI can negatively alter 
the results (14, 16, 21). In one study, out of 2114 patients with 
chronic liver disease, liver stiffness could not be evaluated in 
4.5% of patients, and BMI of >28 kg/m2 was suggested to 
be the only factor leading to an error in multivariate analy-
sis (22). In obese patients, TE is difficult to perform, because 
ultrasound vibrations are often attenuated in the subcutane-
ous tissue. This condition is usually observed in patients with 
NAFLD (23, 24). In the present study, nearly 43 patients out 
of 72 exhibited a BMI of >25 kg/m2, suggesting that BMI 
interfered with the specificity of TE. Nevertheless, future 
studies are needed to confirm the hypothesis.
Commonly associated comorbidities, including type 2 
diabetes mellitus, dyslipidemia, obesity, and hypertension, 
are associated with the manifestations of NAFLD (15, 25). 
Such comorbidities can result in significant morbidity and 
mortality. In the present study, out of 72 patients, 43 (59.6%) 
suffered from diabetes mellitus, the most associated comor-
bidity (26). The presence of comorbidities highlights the 
unmet requirement of early diagnosis and treatment of these 
Table 3: Diagnostic analysis of Fibroscan with liver biopsy







Fibroscan Yes 41 16 0.89 0.38 0.71 0.72 0.67
No 5 10
The values represent the number of patients.
conditions in successfully managing patients with NAFLD. 
Diagnosing and managing such comorbidities on a large 
scale can remarkably improve the quality of life of patients 
with NAFLD (26). Moreover, as observed in the present 
study, hypothyroidism, hypertension, and dyslipidemia are 
the emerging contributors to the development of NAFLD.
In the present study, TE was reported to be 71% accurate 
in detecting the severity of fibrosis. Compliant with the liter-
ature, the present study proposes that considering the inva-
siveness of liver biopsy, TE can be implemented in clinical 
practice as a noninvasive alternative diagnostic method for 
assessing the severity of fibrosis in patients with NAFLD 
(16, 27). This may also be attributable to the major draw-
backs of liver biopsy, mainly sampling variability. Often a 
biopsy specimen 1.5 cm in length and 1.2–2 mm in diame-
ter is adequate for the diagnosis (28). However, sampling is 
associated with human error and other relevant factors. This 
sampling variability can potentially alter the staging of fibro-
sis and diagnosis of patients with NAFLD (14).
TE is a better modality than endoscopy as it can detect 
cases undiagnosed by endoscopy (29). In addition, as eval-
uated by Ghamdi et al., in the case of cirrhosis, TE can 
prognosticate the presence of varices, although it cannot 
differentiate between the size of varices—small or large (30). 
However, the present study suggests that TE and endos-
copy are significantly correlated in terms of size of varices 
and degree of severity. This disagreement could be because 
Ghamdi et al. enrolled patients with cirrhosis only, whereas 
the present study included patients with varying degrees of 
fibrosis for a more comprehensive analysis (30).
The findings help hypothesize that endoscopy findings and 
biopsy findings are poorly correlated in the case of NAFLD 
(Table 2). Moreover, the sample size included in the present 
study was remarkably small to make any solid conclusion. 
Thus, future studies with a larger sample size are required to 
confirm the correlation between liver biopsy and endoscopy.
After a liver biopsy, nearly 30, 0.3, and 0.01% of patients 
experience pain, severe complications, and death, respec-
tively (31, 32). Owing to a high prevalence of NAFLD, draw-
backs of liver biopsy, and reliability of noninvasive tests, TE 
is more feasible than liver biopsy; and thus, the TE scoring 
Bachhav G et al.
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